-

Lost Money in Harmony Biosciences Holdings Inc.?

Gibbs Law Group Investigates Potential Securities Law Violations

OAKLAND, Calif.--(BUSINESS WIRE)--Shares of Harmony Biosciences plummeted 27% on Tuesday, March 28, 2023, after Scorpion Capital published a report alleging that serious health risks, including sudden death, occurred during foreign drug trials of Harmony Bioscience’s drug, Wakix. The report further alleges that the company concealed information from the FDA that would have prevented Wakix’s 2019 approval. Gibbs Law Group is looking into a potential Harmony Biosciences Class Action Lawsuit on behalf of investors who lost money in Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY).

To speak with an attorney regarding this class action lawsuit investigation, click here or call (888) 410-2925.

On Tuesday, March 28, 2023, Scorpion Capital released an investigative report claiming that pharmaceutical company Harmony Biosciences’ narcolepsy drug, Wakix, is a repeat of another similar drug that the FDA previously pulled from the market due to cardiac toxicity. The report details “12 sudden deaths in the foreign clinical trials, all in the drug arm, none in placebo" and alleges that the company provided “sham safety studies” that misled the FDA into approving the drug back in 2019. Scorpion Capital adds that it obtained “dozens of serious adverse event reports” from the FDA that “paint a devastating picture of the drug’s risk to even young, otherwise healthy patients,” and it is now planning to file a Citizen’s Petition with the FDA to request withdrawal of Wakix’s approval.

Following this news, Harmony Biosciences’ stock price dropped 27%, causing significant losses for investors.

What Should Harmony Biosciences Investors Do?

If you invested in Harmony Biosciences, visit our website or contact our securities team directly at (888) 410-2925 to discuss how you may be able to recover your losses. Our investigation concerns whether Harmony Biosciences has violated federal securities laws.

About Gibbs Law Group

Gibbs Law Group represents individual and institutional investors throughout the country in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the world’s largest corporations, and our attorneys have received numerous honors for their work, including “Best Lawyers in America,” “Top Plaintiff Lawyers in California,” “California Lawyer Attorney of the Year,” “Top Class Action Attorneys Under 40,” “Consumer Protection MVP,” and “Top Cybersecurity/ Privacy Attorneys Under 40.”

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

EILEEN EPSTEIN CARNEY
PHONE: 510.350.9728
EMAIL: EJE@CLASSLAWGROUP.COM

Gibbs Law Group

NASDAQ:HRMY

Release Summary
Gibbs Law Group is investigating potential claims on behalf of Harmony Biosciences (HRMY) investors.
Release Versions
$Cashtags
Hashtags

Contacts

EILEEN EPSTEIN CARNEY
PHONE: 510.350.9728
EMAIL: EJE@CLASSLAWGROUP.COM

More News From Gibbs Law Group

Flock License Plate Cameras Face Class Action Lawsuit by Gibbs Mura, A Law Group

OAKLAND, Calif.--(BUSINESS WIRE)--Oakland-based law firm Gibbs Mura has filed a class action lawsuit against Flock Safety for allegedly using its license plate cameras to share millions of Californians' daily movements with law enforcement agencies, violating California privacy laws. Gibbs Mura filed the lawsuit on February 26, 2026 in San Francisco Superior Court with Milberg PLLC, another leading plaintiff-side firm. The firms continue to investigate claims on behalf of additional Californian...

Lost Money in Hub Group (NASDAQ: HUBG)? Investors Urged to Contact Award-Winning Firm, Gibbs Mura

OAKLAND, Calif.--(BUSINESS WIRE)--Gibbs Mura continues to investigate a potential securities class action lawsuit on behalf of Hub Group, Inc. investors....

Lost Money in Kyndryl Holdings (NYSE: KD)? Gibbs Mura Is Investigating Potential Legal Claims on Behalf of Kyndryl Holdings Investors

OAKLAND, Calif.--(BUSINESS WIRE)--Shares of Kyndryl Holdings, Inc. fell over 54% in intraday trading on February 9, 2026, after the company disclosed it is launching an internal review of its account practices, delayed its quarterly filing, and announced the departure of its Chief Financial Officer and General Counsel. Gibbs Mura is investigating a potential Kyndryl Holdings, Inc. (NYSE: KD) Securities Class Action Lawsuit concerning whether Kyndryl Holdings has violated federal securities laws...
Back to Newsroom